Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Antonin Schmitt"'
Autor:
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. Objectives: This work aimed to describe the pha
Externí odkaz:
https://doaj.org/article/17dc600b679a41a78f45ee1236fd3361
Autor:
Amira Sayed Khan, Aziz Hichami, Babar Murtaza, Marie-Laure Louillat-Habermeyer, Christophe Ramseyer, Maryam Azadi, Semen Yesylevskyy, Floriane Mangin, Frederic Lirussi, Julia Leemput, Jean-Francois Merlin, Antonin Schmitt, Muhtadi Suliman, Jérôme Bayardon, Saeed Semnanian, Sylvain Jugé, Naim Akhtar Khan
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 15, Iss 3, Pp 633-663 (2023)
Background & Aims: The spontaneous preference for dietary lipids is principally regulated by 2 lingual fat taste receptors, CD36 and GPR120. Obese animals and most of human subjects exhibit low orosensory perception of dietary fat because of malfunct
Externí odkaz:
https://doaj.org/article/faac987bf7904e528f779ff44b123109
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Esophageal cancer is a cancer with poor prognosis and the standard 1st line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of se
Externí odkaz:
https://doaj.org/article/fb43c09a336148f89968870d2201a771
Autor:
Tarik Hadi, Christophe Ramseyer, Thomas Gautier, Pierre-Simon Bellaye, Tatiana Lopez, Antonin Schmitt, Sarah Foley, Semen Yesylevskyy, Thibault Minervini, Romain Douhard, Lucile Dondaine, Lil Proukhnitzky, Samir Messaoudi, Maeva Wendremaire, Mathieu Moreau, Fabrice Neiers, Bertrand Collin, Franck Denat, Laurent Lagrost, Carmen Garrido, Frederic Lirussi
Publikováno v:
JCI Insight, Vol 5, Iss 24 (2020)
In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL, respectively) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mi
Externí odkaz:
https://doaj.org/article/9e34d234f6474b3c802dff02ce66a9fe
Autor:
Alexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, Isabelle Desmoulins, Audrey Hennequin, Didier Mayeur, Jean-David Fumet, Sylvain Ladoire, Zoé Tharin, Siavoshe Ayati, Silvia Ilie, Bernard Royer, Antonin Schmitt
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1708 (2021)
Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils fro
Externí odkaz:
https://doaj.org/article/5646a4677cb04fe080a4b1126b7ca586
Autor:
Bernard Royer, Courèche Kaderbhaï, Jean-David Fumet, Audrey Hennequin, Isabelle Desmoulins, Sylvain Ladoire, Siavoshe Ayati, Didier Mayeur, Sivia Ilie, Antonin Schmitt
Publikováno v:
Pharmaceuticals, Vol 14, Iss 3, p 181 (2021)
Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient
Externí odkaz:
https://doaj.org/article/432e519ddc6a449fa9db102985069422
Autor:
Marine Dolat, Pauline Macaire, Françoise Goirand, Julie Vincent, Audrey Hennequin, Rémi Palmier, Leïla Bengrine-Lefevre, François Ghiringhelli, Bernard Royer, Antonin Schmitt
Publikováno v:
Pharmaceuticals, Vol 13, Iss 11, p 416 (2020)
In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance an
Externí odkaz:
https://doaj.org/article/2727cb6f3dc8433c8d2343ce7077980a
Autor:
Pascale Dielenseger, Carla Matta, Antoine Angelergues, Paule Augereau, Dominique Berton, Michel Fabbro, Claire Falandry, Philippe Follana, Laurence Gladieff, Florence Joly, Jean-Emmanuel Kurtz, Marie-Ange Mouret-Reynier, Antonin Schmitt, Florian Scotté, Coralie Marjollet, Frédéric Selle
Publikováno v:
Bulletin Infirmier du Cancer. 23:45-58
Autor:
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, Antoine Angelergues, Paule Augereau, Dominique Berton, Pascale Dielenseger, Michel Fabbro, Claire Falandry, Philippe Follana, Laurence Gladieff, Florence Joly, Jean-Emmanuel Kurtz, Carla Matta, Marie-Ange Mouret-Reynier, Antonin Schmitt, Florian Scotté, Coralie Marjollet, Anne Floquet
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, 2022, 109 (12), pp.1245-1261. ⟨10.1016/j.bulcan.2022.06.011⟩
Bulletin du Cancer, 2022, 109 (12), pp.1245-1261. ⟨10.1016/j.bulcan.2022.06.011⟩
International audience; Objective > Despite an increasing number of therapeutic indications, there are no specific recommendations regarding the management of PARP inhibitors other than what is specified in the SmPC of each substance. A Delphi French
Autor:
Jean-Sebastien Frenel, Loic Campion, Antonin Schmitt, Patricia De Cremoux, Elsa Rossignol, Celine Renaudeau, Marie Robert, Jean-Marie Bard, Christine Bobin-Dubigeon, Mario Campone
Publikováno v:
Cancer Research. 82:P1-07
Introduction: Endoxifen exposure, the most active metabolite of tamoxifen, may be a better predictor of tamoxifen efficacy, than CYP2D6 genotypes. However, conflicting results have been reported so far. We evaluated prospectively the impact of 5 week